176 related articles for article (PubMed ID: 37357030)
1. Cross-Study Comparisons of JAK2 Inhibitors in Myelofibrosis: Risks and Recommendations.
Mascarenhas J; Mesa R
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):714-718. PubMed ID: 37357030
[TBL] [Abstract][Full Text] [Related]
2. How many JAK inhibitors in myelofibrosis?
Ferreira BV; Harrison C
Best Pract Res Clin Haematol; 2014 Jun; 27(2):187-95. PubMed ID: 25189729
[TBL] [Abstract][Full Text] [Related]
3. Investigational Janus kinase inhibitors in development for myelofibrosis.
Bose P; Abou Zahr A; Verstovsek S
Expert Opin Investig Drugs; 2017 Jun; 26(6):723-734. PubMed ID: 28441920
[TBL] [Abstract][Full Text] [Related]
4. Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis.
Del Rosario M; Tsai H; Dasanu CA
J Oncol Pharm Pract; 2018 Apr; 24(3):226-228. PubMed ID: 28436280
[TBL] [Abstract][Full Text] [Related]
5. Comparison of clinical outcomes between transplant and nontransplant therapies in myelofibrosis following failure of first-line JAK-inhibitor.
England JT; Atenafu EG; Kennedy JA; Goraya B; Cheung V; Nye T; Gauthier K; Davidson MB; Bankar A; Sibai H; Maze D; Viswabandya A; Gupta V
Am J Hematol; 2023 May; 98(5):E127-E129. PubMed ID: 36814403
[No Abstract] [Full Text] [Related]
6. What is next beyond janus kinase 2 inhibitors for primary myelofibrosis?
Santos FP; Verstovsek S
Curr Opin Hematol; 2013 Mar; 20(2):123-9. PubMed ID: 23385614
[TBL] [Abstract][Full Text] [Related]
7. JAK inhibition in myelofibrosis: how to sequence treatment in this new era of multiple options.
Stein BL
Leuk Lymphoma; 2023 Feb; 64(2):292-299. PubMed ID: 36301740
[TBL] [Abstract][Full Text] [Related]
8. [Research Progress on Effect of JAK Inhibitors on Myelofibrosis- Review].
Liu JX; Chen W; Xu KL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Feb; 26(1):283-286. PubMed ID: 29397859
[TBL] [Abstract][Full Text] [Related]
9. First Approval of Pacritinib as a Selective Janus Associated Kinase-2 Inhibitor for the Treatment of Patients with Myelofibrosis.
De SK
Anticancer Agents Med Chem; 2023; 23(12):1355-1360. PubMed ID: 36959157
[TBL] [Abstract][Full Text] [Related]
10. Janus activated kinase inhibition in myelofibrosis.
Malhotra H
Indian J Cancer; 2012; 49(3):260-5. PubMed ID: 23238141
[TBL] [Abstract][Full Text] [Related]
11. Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis.
Menghrajani K; Boonstra PS; Mercer JA; Perkins C; Gowin KL; Weber AA; Mesa R; Gotlib JR; Wang L; Singer JW; Talpaz M
Leuk Lymphoma; 2019 Apr; 60(4):1036-1042. PubMed ID: 30234400
[TBL] [Abstract][Full Text] [Related]
12. The development, safety and efficacy of pacritinib for the treatment of myelofibrosis.
Jain T; Mesa R
Expert Rev Anticancer Ther; 2016 Nov; 16(11):1101-1108. PubMed ID: 27598824
[TBL] [Abstract][Full Text] [Related]
13. Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors.
Randhawa J; Ostojic A; Vrhovac R; Atallah E; Verstovsek S
J Hematol Oncol; 2012 Aug; 5():43. PubMed ID: 22852872
[TBL] [Abstract][Full Text] [Related]
14. Clinical and molecular correlates of JAK-inhibitor therapy failure in myelofibrosis: long-term data from a molecularly annotated cohort.
England JT; McNamara CJ; Kennedy JA; Capo-Chichi JM; Huang J; Arruda A; Nye T; Cheung V; Claudio JO; Maze D; Sibai H; Tierens A; Tsui H; Bankar A; Xu W; Stockley T; Gupta V
Leukemia; 2022 Jun; 36(6):1689-1692. PubMed ID: 35347238
[No Abstract] [Full Text] [Related]
15. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
[TBL] [Abstract][Full Text] [Related]
16. Management of myelofibrosis after ruxolitinib failure.
Bose P; Verstovsek S
Leuk Lymphoma; 2020 Aug; 61(8):1797-1809. PubMed ID: 32297800
[TBL] [Abstract][Full Text] [Related]
17. Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis.
Tvorogov D; Thomas D; Liau NPD; Dottore M; Barry EF; Lathi M; Kan WL; Hercus TR; Stomski F; Hughes TP; Tergaonkar V; Parker MW; Ross DM; Majeti R; Babon JJ; Lopez AF
Sci Adv; 2018 Nov; 4(11):eaat3834. PubMed ID: 30498775
[TBL] [Abstract][Full Text] [Related]
18. How I treat myelofibrosis after failure of JAK inhibitors.
Pardanani A; Tefferi A
Blood; 2018 Aug; 132(5):492-500. PubMed ID: 29866811
[TBL] [Abstract][Full Text] [Related]
19. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
20. Balancing efficacy and safety of JAK inhibitors in myelofibrosis.
Passamonti F
Leuk Res; 2014 Mar; 38(3):290-1. PubMed ID: 24444869
[No Abstract] [Full Text] [Related]
[Next] [New Search]
